{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Lin SY"],"pubmed_abstract":["<b>Background:</b> Whether diabetes mellitus (DM) patients with chronic kidney disease (CKD) can glean individual renal benefit from dihydropyridine calcium channel blockers (DCCBs) remains to be determined. We conducted a nationwide, population-based, propensity score matching cohort study to examine the effect of DCCBs on CKD progression in DM patients with CKD. <b>Methods:</b> One million individuals were randomly sampled from Taiwan's National Health Insurance Research Database. The study cohort consisted of DM patients with CKD who used DCCBs. The comparison cohort was propensity-matched for demographic characteristics and comorbidities. The endpoint was advanced CKD or end-stage renal disease (ESRD). The Cox proportional hazards model was used to calculate the risks. <b>Results:</b> "],"journal":["Frontiers in pharmacology"],"pagination":["786203"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8959929"],"repository":["biostudies-literature"],"pubmed_title":["Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study."],"pmcid":["PMC8959929"],"pubmed_authors":["Hsu WH","Lin CL","Lin CC","Kao CH","Hsu CY","Lin SY"],"additional_accession":[]},"is_claimable":false,"name":"Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.","description":"<b>Background:</b> Whether diabetes mellitus (DM) patients with chronic kidney disease (CKD) can glean individual renal benefit from dihydropyridine calcium channel blockers (DCCBs) remains to be determined. We conducted a nationwide, population-based, propensity score matching cohort study to examine the effect of DCCBs on CKD progression in DM patients with CKD. <b>Methods:</b> One million individuals were randomly sampled from Taiwan's National Health Insurance Research Database. The study cohort consisted of DM patients with CKD who used DCCBs. The comparison cohort was propensity-matched for demographic characteristics and comorbidities. The endpoint was advanced CKD or end-stage renal disease (ESRD). The Cox proportional hazards model was used to calculate the risks. <b>Results:</b> ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T07:35:04.144Z","creation":"2025-04-04T07:35:04.144Z"},"accession":"S-EPMC8959929","cross_references":{"pubmed":["35355728"],"doi":["10.3389/fphar.2022.786203"]}}